BerGenBio and Oncoinvent Poised to Merge, Ushering in a New Era for Radiopharmaceutical Cancer Therapies
Bergen, Norway – June 30, 2025 – In a significant development for the field of oncology, BerGenBio ASA and Oncoinvent AS have announced a proposed merger that, upon completion, will unite two promising companies at the forefront of innovative cancer treatment. The strategic combination aims to leverage their complementary strengths and pipelines to accelerate the development and commercialization of advanced therapies for patients battling cancer.
The announcement, published by PR Newswire Healthring, details a comprehensive plan that includes both the merger of the two entities and a fully underwritten rights issue to support the combined company’s future growth. This dual approach signals a robust commitment to advancing their shared vision.
Oncoinvent, recognized as a rising innovator in radiopharmaceutical cancer therapies, brings a wealth of expertise in developing targeted treatments that utilize radioactive isotopes to selectively destroy cancer cells. Their pioneering work in this specialized area of medicine holds considerable promise for patients who may not respond to conventional therapies or who require more precise treatment modalities.
BerGenBio, a clinical-stage biopharmaceutical company, has been dedicated to developing novel cancer therapies focused on modulating the tumor microenvironment, particularly through its expertise in developing small molecule inhibitors of receptor tyrosine kinases, such as AXL. Their research efforts have been geared towards overcoming treatment resistance and enhancing the efficacy of existing cancer treatments.
The proposed merger is expected to create a synergistic entity with a diversified portfolio and a strengthened platform for drug discovery and development. By combining Oncoinvent’s radiopharmaceutical capabilities with BerGenBio’s expertise in novel immunotherapy targets, the merged company is positioned to explore and advance a broader range of therapeutic avenues. This integration could potentially unlock new treatment paradigms and offer patients more effective and personalized options.
The accompanying fully underwritten rights issue is a crucial component of the merger, designed to provide the necessary capital to fuel ongoing clinical trials, expand research and development initiatives, and support potential future commercialization efforts. This financial strategy underscores the confidence in the combined entity’s long-term prospects and its ability to translate scientific innovation into tangible patient benefits.
While the specific terms of the merger and the rights issue are subject to customary closing conditions and regulatory approvals, the announcement marks a pivotal moment for both organizations and the broader oncology landscape. Stakeholders and the medical community will be keenly watching as this strategic union progresses, with the shared hope that it will lead to significant advancements in the fight against cancer.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue’ at 2025-06-30 20:28. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.